JPMorgan Chase & Co. set a $85.00 target price on Eli Lilly and Co. (NYSE:LLY) in a research note released on Thursday morning. The brokerage currently has a buy rating on the stock.

Several other research analysts also recently commented on the company. Morgan Stanley set a $73.00 target price on Eli Lilly and and gave the stock a hold rating in a research note on Thursday. Atlantic Securities downgraded Eli Lilly and from an overweight rating to a neutral rating in a research note on Friday. BMO Capital Markets downgraded Eli Lilly and from an outperform rating to a market perform rating and set a $64.00 target price for the company. in a research note on Wednesday. Citigroup Inc. reissued a buy rating on shares of Eli Lilly and in a research note on Tuesday, November 8th. Finally, Jefferies Group reissued a buy rating and set a $100.00 target price (down previously from $105.00) on shares of Eli Lilly and in a research note on Friday, October 28th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of Buy and a consensus price target of $92.34.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Shares of Eli Lilly and (NYSE:LLY) traded up 1.65% on Thursday, reaching $69.12. 8,620,682 shares of the company’s stock were exchanged. The stock has a market cap of $73.11 billion, a P/E ratio of 30.07 and a beta of 0.28. The company’s 50 day moving average price is $76.69 and its 200-day moving average price is $77.92. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $88.16.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 25th. The company reported $0.88 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by $0.08. The business had revenue of $5.19 billion for the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. The firm’s revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 EPS. Equities analysts forecast that Eli Lilly and will post $3.55 EPS for the current fiscal year.

WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2016/11/25/eli-lilly-and-co-lly-given-a-85-00-price-target-at-jpmorgan-chase-co.html.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be issued a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date is Thursday, November 10th. Eli Lilly and’s payout ratio is 88.70%.

In other Eli Lilly and news, insider Maria A. Crowe sold 2,248 shares of the stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the transaction, the insider now directly owns 94,319 shares in the company, valued at approximately $7,674,737.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of LLY. Vanguard Group Inc. boosted its position in Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock worth $4,979,889,000 after buying an additional 1,350,329 shares during the last quarter. Franklin Resources Inc. boosted its position in Eli Lilly and by 2.5% in the second quarter. Franklin Resources Inc. now owns 28,430,876 shares of the company’s stock worth $2,238,939,000 after buying an additional 685,898 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Eli Lilly and by 1.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 26,674,046 shares of the company’s stock worth $2,100,581,000 after buying an additional 289,681 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Eli Lilly and by 3.0% in the second quarter. JPMorgan Chase & Co. now owns 23,184,616 shares of the company’s stock worth $1,825,790,000 after buying an additional 668,184 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its position in Eli Lilly and by 2.5% in the third quarter. BlackRock Fund Advisors now owns 17,629,570 shares of the company’s stock worth $1,414,949,000 after buying an additional 423,179 shares during the last quarter. Hedge funds and other institutional investors own 75.11% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.